|
1
|
Chronic calcific pancreatitis: combination ERCP and extracorporeal shock wave lithotripsy for pancreatic duct stones.
|
South Med J
|
2010
|
1.52
|
|
2
|
Prostate cancer disparities in South Carolina: early detection, special programs, and descriptive epidemiology.
|
J S C Med Assoc
|
2006
|
1.50
|
|
3
|
Capromab pendetide scanning has a potential role in optimizing patient selection for salvage cryosurgical ablation of the prostate.
|
Urology
|
2010
|
1.43
|
|
4
|
Evaluation of modern pathological criteria for positive margins in radical prostatectomy specimens and their use for predicting biochemical recurrence.
|
BJU Int
|
2008
|
1.43
|
|
5
|
The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy.
|
Cancer Biol Ther
|
2007
|
1.27
|
|
6
|
Preliminary treatment considerations among men with newly diagnosed prostate cancer.
|
Am J Manag Care
|
2010
|
1.24
|
|
7
|
Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer.
|
Mol Ther
|
2008
|
1.19
|
|
8
|
Involvement of sphingolipids in apoptin-induced cell killing.
|
Mol Ther
|
2006
|
1.16
|
|
9
|
Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions.
|
World J Urol
|
2010
|
1.12
|
|
10
|
Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer.
|
Mol Immunol
|
2007
|
1.12
|
|
11
|
Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance.
|
J Clin Endocrinol Metab
|
2012
|
1.08
|
|
12
|
Acid ceramidase inhibition: a novel target for cancer therapy.
|
Front Biosci
|
2008
|
1.07
|
|
13
|
Provider and partner interactions in the treatment decision-making process for newly diagnosed localized prostate cancer.
|
BJU Int
|
2011
|
0.98
|
|
14
|
Partial segmental thrombosis of corpus cavernosum: case report and review of world literature.
|
Urology
|
2005
|
0.97
|
|
15
|
Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse.
|
J Clin Invest
|
2013
|
0.96
|
|
16
|
Community-acquired methicillin-resistant Staphylococcus aureus prostatic abscess.
|
Urology
|
2004
|
0.96
|
|
17
|
Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
|
Urology
|
2008
|
0.93
|
|
18
|
Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice.
|
BJU Int
|
2005
|
0.93
|
|
19
|
Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection.
|
Int J Cancer
|
2008
|
0.92
|
|
20
|
Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy.
|
Expert Opin Ther Targets
|
2009
|
0.91
|
|
21
|
Diagnostic performance of In-111 capromab pendetide SPECT/CT in localized and metastatic prostate cancer.
|
Clin Nucl Med
|
2011
|
0.88
|
|
22
|
Bacillus calmette-guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer.
|
Rev Urol
|
2008
|
0.87
|
|
23
|
The multi-disciplinary management of high-risk prostate cancer.
|
Urol Oncol
|
2009
|
0.86
|
|
24
|
Inferior vena cava reconstruction using fresh inferior vena cava allograft following caval resection for leiomyosarcoma: midterm results.
|
J Vasc Surg
|
2007
|
0.84
|
|
25
|
The present and future for gene and viral therapy of directly accessible prostate and squamous cell cancers of the head and neck.
|
Future Oncol
|
2005
|
0.83
|
|
26
|
Managing prostate cancer: the role of hormone therapy.
|
Can J Urol
|
2007
|
0.82
|
|
27
|
Pathologically confirmed port site metastasis after laparoscopic radical prostatectomy: case report and literature review.
|
Urology
|
2007
|
0.82
|
|
28
|
Considering racial and ethnic preferences in communication and interactions among the patient, family member, and physician following diagnosis of localized prostate cancer: study of a US population.
|
Int J Gen Med
|
2011
|
0.81
|
|
29
|
Camptothecin analogues and vinblastine in the treatment of renal cell carcinoma: an in vivo study using a human orthotopic renal cancer xenograft.
|
Urol Oncol
|
2003
|
0.81
|
|
30
|
The emergence of radioimmunoscintigraphy for prostate cancer.
|
Rev Urol
|
2006
|
0.80
|
|
31
|
Detection of mitochondrial deoxyribonucleic acid alterations in urine from urothelial cell carcinoma patients.
|
Int J Cancer
|
2011
|
0.80
|
|
32
|
Concomitant intraoperative renal artery embolization and resection of complex renal carcinoma.
|
J Vasc Surg
|
2003
|
0.80
|
|
33
|
Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer.
|
World J Urol
|
2013
|
0.79
|
|
34
|
Avoiding obsolescence in advanced prostate cancer management: a guide for urologists.
|
BJU Int
|
2015
|
0.79
|
|
35
|
Impact of prostate cancer on sexual relationships: a longitudinal perspective on intimate partners' experiences.
|
J Sex Med
|
2013
|
0.79
|
|
36
|
Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspective.
|
Support Care Cancer
|
2013
|
0.79
|
|
37
|
Salvage cryosurgical ablation of the prostate for local recurrence after radiation therapy: improved outcomes utilizing a capromab pendetide scan and biopsy algorithm.
|
Can J Urol
|
2007
|
0.78
|
|
38
|
Willingness to pay for prostate cancer treatment among patients and their family members at 1 year after diagnosis.
|
Value Health
|
2012
|
0.77
|
|
39
|
Salvage options for biochemical recurrence after primary therapy for prostate cancer.
|
Can J Urol
|
2007
|
0.77
|
|
40
|
Editorial comment.
|
Urology
|
2012
|
0.75
|
|
41
|
Perineal prostatectomy in the age of minimally invasive surgery.
|
J Ark Med Soc
|
2008
|
0.75
|
|
42
|
PC-SPES withdrawal response.
|
Acta Oncol
|
2004
|
0.75
|
|
43
|
Bladder cancer--resection/ablation.
|
Surg Oncol Clin N Am
|
2005
|
0.75
|